Anti-Obesity Drugs Market Research Report by Treatment Type [Appetite Suppressants (Serotonin Norepinephrine Reuptake Inhibitors, Selective Serotonin 2C Receptor Agonists, Norepinephrine Dopamine Reuptake Inhibitors), Lipase Inhibitors, GLP-1 Receptor Ago
Description
The global anti-obesity drugs market is expected to expand to USD 326.8969 billion by 2035, registering a CAGR of 25.82% during 2025–2035. Anti-obesity drugs are medications designed to aid weight loss by reducing appetite, increasing feelings of fullness, or limiting fat absorption in the body. They are typically prescribed for individuals with obesity or overweight who face health risks such as diabetes, heart disease, or hypertension. These drugs are often used alongside lifestyle changes like diet and exercise for effective weight management.
The global anti-obesity drugs market is being influenced by the rising demand for non-invasive weight management methods. As obesity has become a pandemic, causing the death of hundreds of millions of people worldwide, patients and doctors are searching for the safest and least painful ways to perform bariatric surgery. Advanced pharmacological therapies are especially as GLP-1 receptor agonists and dual receptor medicines like tirzepatide, are achieving weight reduction to never-before-seen levels, along with metabolic health improvement. Companies in the pharmaceutical industry, such as Eli Lilly and Novo Nordisk, are the main drivers of this change. Through new product launches and visa market entry, they are targeting cities with increasing obesity issues, including Asia and Latin America.
The government is supporting these actions with particular large-scale projects, including the imposition of tax on sweet products, finance for obesity research, and promotion of healthy lifestyles among the population. The monetary cost of diseases related to obesity is very high, and the world is expected to pay more than $3 trillion annually by 2030, which is putting a lot of pressure on health systems to adopt efficient treatments.
Long-term safety concerns and regulatory approvals still pose obstacles. Improvements in the tolerability of drugs and the application of combination therapy are extending the range of treatment options. With a clinical trials program of drugs, the public health crisis continues strongly, and policy measures are positive; the anti-obesity drugs market is expected to have a considerable and long-term upward trend in the next ten years.
Market Segmentation Insights
Based on the drug type, the global market is classified into prescription drugs and over-the-counter drugs.
Oral and subcutaneous are part of the route of administration of the global anti-obesity drugs market.
In terms of the mechanism in action, the global market is divided into peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs.
GLP-1 receptor agonists, appetite suppressants, lipase inhibitors, combination drugs, and others are the treatment type category of the global market. Appetite suppressants are further segmented into Serotonin Norepinephrine reuptake inhibitors, selective serotonin 2C receptor agonists, and Norepinephrine Dopamine Reuptake inhibitors.
Depending on the distribution channel, the global anti-obesity drugs market is segmented into hospital, retail, and online pharmacies.
Regional Perspectives
North America continues to be the greatest market for obesity drugs. This is caused by the high prevalence of obesity in the region and a healthcare system that is agreeable to the introduction of pharmacological treatments in general. The bulk of the demand is accounted for by the U.S., where more than 42% of the adult population is obese. The fact that Medicare is going to cover anti-obesity treatments has made it possible for millions more people to get access to it, while the FDA’s quick approvals of drugs such as semaglutide have made the uptake quite rapid. The big pharma companies are implementing the plan of conducting clinical trials in this area and launching their products here first, as they know a large number of patients will respond and be there at the start of the trend. In addition, the market potential is further enhanced by the solid insurance coverage and private healthcare expenditure.
Europe, on the other hand, has a market that is expected to grow due to the fact that it has extensive public healthcare plans, which make highly specialized and costly obesity treatments accessible to a wide variety of people. The UK and Germany are examples of countries that have drawn up national guidelines that position the management of obesity as a part of maintaining overall health. The problem of obesity among the elderly is becoming more and more serious, and hence, a larger share of health costs is being attributed to weight-related causes. The EMA is approving PAM-based drugs like GLP-1 receptor injections for the next generation of therapy for eager patients. Research cooperation between EU countries has significantly shortened the time needed to bring fresh anti-obesity medications to the market.
One of the fastest-growing regions is the Asia-Pacific, which is experiencing a rise in obesity caused by increased incomes and urbanization. The situation in countries like China and India is such that there is malnutrition in the rural areas, while the urban population is overeating. Governments are not only licensing the new drugs but also launching awareness campaigns that mostly focus on diabetes-related obesity. Local pharmaceutical companies are collaborating with international companies to release new drugs at more competitive prices.
In South America, urban lifestyle changes and increased processed food consumption are driving higher obesity levels, especially in Brazil and Argentina. Middle-class growth has improved healthcare access, expanding the customer base for anti-obesity drugs. Governments are recognizing obesity’s economic impact, launching programs for prevention and treatment. Collaborations between multinational drug makers and local distributors are ensuring supply to remote and underserved areas. Regional marketing strategies often emphasize metabolic health benefits to resonate with patient priorities.
The Middle East & Africa market is shaped by a rapid rise in obesity-related chronic illnesses such as diabetes and hypertension. Gulf countries, in particular, face some of the world’s highest obesity rates, prompting large-scale public health initiatives. Economic development has increased disposable incomes, enabling greater access to premium drugs. Governments are funding national weight-loss campaigns and supporting medical conferences to build healthcare provider awareness. In Africa, early adoption is concentrated in urban centers with stronger private healthcare infrastructure.
Major Competitors
Key competitors in the global anti-obesity drugs market are Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, and CHEPLAPHARM Arzneimittel GmbH.
The global anti-obesity drugs market is being influenced by the rising demand for non-invasive weight management methods. As obesity has become a pandemic, causing the death of hundreds of millions of people worldwide, patients and doctors are searching for the safest and least painful ways to perform bariatric surgery. Advanced pharmacological therapies are especially as GLP-1 receptor agonists and dual receptor medicines like tirzepatide, are achieving weight reduction to never-before-seen levels, along with metabolic health improvement. Companies in the pharmaceutical industry, such as Eli Lilly and Novo Nordisk, are the main drivers of this change. Through new product launches and visa market entry, they are targeting cities with increasing obesity issues, including Asia and Latin America.
The government is supporting these actions with particular large-scale projects, including the imposition of tax on sweet products, finance for obesity research, and promotion of healthy lifestyles among the population. The monetary cost of diseases related to obesity is very high, and the world is expected to pay more than $3 trillion annually by 2030, which is putting a lot of pressure on health systems to adopt efficient treatments.
Long-term safety concerns and regulatory approvals still pose obstacles. Improvements in the tolerability of drugs and the application of combination therapy are extending the range of treatment options. With a clinical trials program of drugs, the public health crisis continues strongly, and policy measures are positive; the anti-obesity drugs market is expected to have a considerable and long-term upward trend in the next ten years.
Market Segmentation Insights
Based on the drug type, the global market is classified into prescription drugs and over-the-counter drugs.
Oral and subcutaneous are part of the route of administration of the global anti-obesity drugs market.
In terms of the mechanism in action, the global market is divided into peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs.
GLP-1 receptor agonists, appetite suppressants, lipase inhibitors, combination drugs, and others are the treatment type category of the global market. Appetite suppressants are further segmented into Serotonin Norepinephrine reuptake inhibitors, selective serotonin 2C receptor agonists, and Norepinephrine Dopamine Reuptake inhibitors.
Depending on the distribution channel, the global anti-obesity drugs market is segmented into hospital, retail, and online pharmacies.
Regional Perspectives
North America continues to be the greatest market for obesity drugs. This is caused by the high prevalence of obesity in the region and a healthcare system that is agreeable to the introduction of pharmacological treatments in general. The bulk of the demand is accounted for by the U.S., where more than 42% of the adult population is obese. The fact that Medicare is going to cover anti-obesity treatments has made it possible for millions more people to get access to it, while the FDA’s quick approvals of drugs such as semaglutide have made the uptake quite rapid. The big pharma companies are implementing the plan of conducting clinical trials in this area and launching their products here first, as they know a large number of patients will respond and be there at the start of the trend. In addition, the market potential is further enhanced by the solid insurance coverage and private healthcare expenditure.
Europe, on the other hand, has a market that is expected to grow due to the fact that it has extensive public healthcare plans, which make highly specialized and costly obesity treatments accessible to a wide variety of people. The UK and Germany are examples of countries that have drawn up national guidelines that position the management of obesity as a part of maintaining overall health. The problem of obesity among the elderly is becoming more and more serious, and hence, a larger share of health costs is being attributed to weight-related causes. The EMA is approving PAM-based drugs like GLP-1 receptor injections for the next generation of therapy for eager patients. Research cooperation between EU countries has significantly shortened the time needed to bring fresh anti-obesity medications to the market.
One of the fastest-growing regions is the Asia-Pacific, which is experiencing a rise in obesity caused by increased incomes and urbanization. The situation in countries like China and India is such that there is malnutrition in the rural areas, while the urban population is overeating. Governments are not only licensing the new drugs but also launching awareness campaigns that mostly focus on diabetes-related obesity. Local pharmaceutical companies are collaborating with international companies to release new drugs at more competitive prices.
In South America, urban lifestyle changes and increased processed food consumption are driving higher obesity levels, especially in Brazil and Argentina. Middle-class growth has improved healthcare access, expanding the customer base for anti-obesity drugs. Governments are recognizing obesity’s economic impact, launching programs for prevention and treatment. Collaborations between multinational drug makers and local distributors are ensuring supply to remote and underserved areas. Regional marketing strategies often emphasize metabolic health benefits to resonate with patient priorities.
The Middle East & Africa market is shaped by a rapid rise in obesity-related chronic illnesses such as diabetes and hypertension. Gulf countries, in particular, face some of the world’s highest obesity rates, prompting large-scale public health initiatives. Economic development has increased disposable incomes, enabling greater access to premium drugs. Governments are funding national weight-loss campaigns and supporting medical conferences to build healthcare provider awareness. In Africa, early adoption is concentrated in urban centers with stronger private healthcare infrastructure.
Major Competitors
Key competitors in the global anti-obesity drugs market are Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, and CHEPLAPHARM Arzneimittel GmbH.
Table of Contents
186 Pages
- 1 Executive Summary
- 2 Market Introduction
- 2.1 Definition
- 2.2 Scope Of The Study
- 2.3 Research Objective
- 2.4 Market Structure
- 3 Research Methodology
- 3.1 Overview
- 3.2 Data Flow
- 3.2.1 Data Mining Process
- 3.3 Purchased Database:
- 3.4 Secondary Sources:
- 3.4.1 Secondary Research Data Flow:
- 3.5 Primary Research:
- 3.5.1 Primary Research Data Flow:
- 3.5.2 Primary Research: Number Of Interviews Conducted
- 3.5.3 Primary Research: Regional Coverage
- 3.6 Approaches For Market Size Estimation:
- 3.6.1 Revenue Analysis Approach
- 3.7 Data Forecasting
- 3.7.1 Data Forecasting Type
- 3.8 Data Modeling
- 3.8.1 Microeconomic Factor Analysis:
- 3.8.2 Data Modeling:
- 3.9 Teams And Analyst Contribution
- 4 Market Dynamics
- 4.1 Introduction
- 4.2 Drivers
- 4.2.1 Rising Prevalence Of Obesity
- 4.2.2 Increasing Government Initiatives And Support
- 4.3 Restraints
- 4.3.1 Side Effects And Safety Concerns
- 4.4 Opportunity
- 4.4.1 Focus On Non-surgical Obesity Treatments
- 5 Market Factor Analysis
- 5.1 Porter's Five Forces Model
- 5.1.1 Threat Of New Entrants
- 5.1.2 Bargaining Power Of Suppliers
- 5.1.3 Threat Of Substitutes
- 5.1.4 Bargaining Power Of Buyers
- 5.1.5 Intensity Of Rivalry
- 5.2 Impact Of Covid-19 On Global Anti-obesity Drugs Market
- 5.3 Market Trends
- 5.4 Regulatory Landscape
- 5.4.1 North America
- 5.4.2 Europe
- 5.4.3 Asia-pacific
- 5.4.4 Latin America
- 5.4.5 Middle East And Africa
- 5.5 Unmet Needs
- 5.6 Epidemiology Assessment
- 5.7 Brand And Pipeline Analysis
- 5.8 Pricing Analysis
- 6 Global Anti-obesity Drugs Market, By Treatment Type
- 6.1 Overview
- 6.1 Appetite Suppressants
- 6.1.1 Serotonin-norepinephrine Reuptake Inhibitors
- 6.1.2 Selective Serotonin 2c Receptor Agonists
- 6.1.3 Norepinephrine-dopamine Reuptake Inhibitors (Ndris)
- 6.2 Lipase Inhibitors
- 6.3 Glp-1 Receptor Agonists
- 6.4 Combination Drugs
- 6.5 Others
- 7 Global Anti-obesity Drugs Market, By Drug Type
- 7.1 Overview
- 7.2 Prescription Drugs
- 7.3 Over The Counter Drugs
- 8 Global Anti-obesity Drugs Market, By Mechanism Of Action
- 8.1 Overview
- 8.2 Centrally Acting Anti-obesity Drugs
- 8.3 Peripherally Acting Anti-obesity Drugs
- 9 Global Anti-obesity Drugs Market, By Route Of Administration
- 9.1 Overview
- 9.2 Oral
- 9.3 Subcutaneous
- 10 Global Anti-obesity Drugs Market, By Distribution Channel
- 10.1 Overview
- 10.2 Hospital Pharmacies
- 10.3 Retail Pharmacies
- 10.4 Online Pharmacies
- 11 Global Anti-obesity Drugs Market, By Region
- 11.1 Overview
- 11.2 North America
- 11.2.1 Us
- 11.2.2 Canada
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 France
- 11.3.3 Uk
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Russia
- 11.3.7 Rest Of Europe
- 11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 India
- 11.4.3 Japan
- 11.4.4 South Korea
- 11.4.5 Malaysia
- 11.4.6 Thailand
- 11.4.7 Indonesia
- 11.4.8 Rest Of Asia Pacific
- 11.5 South America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Argentina
- 11.5.4 Rest Of South America
- 11.6 Middle East And Africa
- 11.6.1 Gcc Countries
- 11.6.2 South Africa
- 11.6.3 Rest Of Mea
- 12 Competitive Landscape
- 12.1 Introduction
- 12.2 Market Share Analysis, 2024
- 12.3 Competitor Dashboard
- 12.4 Public Players Stock Summary
- 12.5 Comparative Analysis: Key Players Financial
- 12.1 Key Developments & Growth Strategies
- 12.1.1 Product Approval
- 12.1.2 Marketing Approval
- 12.1.3 Product Expansion
- 12.1.4 Facility Launch
- 12.1.5 Aquisition
- 12.1.6 Agreement
- 13 Company Profiles
- 13.1 Eli Lilly And Company
- 13.1.1 Company Overview
- 13.1.2 Financial Overview
- 13.1.3 Products Offered
- 13.1.4 Key Developments
- 13.1.5 Swot Analysis
- 13.1.6 Key Strategies
- 13.2 Astrazeneca
- 13.2.1 Company Overview
- 13.2.2 Financial Overview
- 13.2.3 Products Offered
- 13.2.4 Key Developments
- 13.2.5 Swot Analysis
- 13.2.6 Key Strategies
- 13.3 Gsk Plc
- 13.3.1 Company Overview
- 13.3.2 Financial Overview
- 13.3.3 Product Offered
- 13.3.4 Key Developments
- 13.3.5 Swot Analysis
- 13.3.6 Key Strategies
- 13.4 Gelesis
- 13.4.1 Company Overview
- 13.4.2 Financial Overview
- 13.4.3 Products Offered
- 13.4.4 Key Developments
- 13.4.5 Key Strategies
- 13.5 Cheplapharm Arzneimittel Gmbh
- 13.5.1 Company Overview
- 13.5.2 Financial Overview
- 13.5.3 Product Offered
- 13.5.4 Key Developments
- 13.5.5 Key Strategies
- 13.6 Novo Nordisk A/S
- 13.6.1 Company Overview
- 13.6.2 Financial Overview
- 13.6.3 Products Offered
- 13.6.4 Key Developments
- 13.6.5 Swot Analysis
- 13.6.6 Key Strategies
- 13.7 Rhythm Pharmaceuticals, Inc.
- 13.7.1 Company Overview
- 13.7.2 Financial Overview
- 13.7.3 Products Offered
- 13.7.4 Key Developments
- 13.7.5 Swot Analysis
- 13.7.6 Key Strategies
- 13.8 Kvk Tech, Inc.
- 13.8.1 Company Overview
- 13.8.2 Financial Overview
- 13.8.3 Products Offered
- 13.8.4 Key Developments
- 13.8.5 Key Strategies
- 13.9 Currax Pharmaceuticals Llc
- 13.9.1 Company Overview
- 13.9.2 Financial Overview
- 13.9.3 Products Offered
- 13.9.4 Key Developments
- 13.9.5 Key Strategies
- 13.10 Vivus Llc
- 13.10.1 Company Overview
- 13.10.2 Financial Overview
- 13.10.3 Products Offered
- 13.10.4 Key Developments
- 13.10.5 Key Strategies
- 14 Data Citations
- List Of Tables
- Table 1 Qfd Modeling For Market Share Assessment
- Table 2 Brand And Pipeline Analysis
- Table 3 Pricing Analysis
- Table 4 Global Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 5 Global Anti-obesity Drugs Market, For Appetite Suppressants, By Region, 2019–2035 (Usd Billion)
- Table 6 Global Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 7 Global Anti-obesity Drugs Market, For Serotonin-norepinephrine Reuptake Inhibitors, By Region, 2019–2035 (Usd Billion)
- Table 8 Global Anti-obesity Drugs Market, For Selective Serotonin 2c Receptor Agonists, By Region, 2019–2035 (Usd Billion)
- Table 9 Global Anti-obesity Drugs Market, For Norepinephrine-dopamine Reuptake Inhibitors (Ndris), By Region, 2019–2035 (Usd Billion)
- Table 10 Global Anti-obesity Drugs Market, For Lipase Inhibitors, By Region, 2019–2035 (Usd Billion)
- Table 11 Global Anti-obesity Drugs Market, For Glp-1 Receptor Agonists, By Region, 2019–2035 (Usd Billion)
- Table 12 Global Anti-obesity Drugs Market, For Combination Drugs, By Region, 2019–2035 (Usd Billion)
- Table 13 Global Anti-obesity Drugs Market, For Others, By Region, 2019–2035 (Usd Billion)
- Table 14 Global Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 15 Global Anti-obesity Drugs Market, For Prescription Drugs, By Region, 2019–2035 (Usd Billion)
- Table 16 Global Anti-obesity Drugs Market, For Over-the-counter Drugs, By Region, 2019–2035 (Usd Billion)
- Table 17 Global Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 18 Global Anti-obesity Drugs Market, For Centrally Acting Anti-obesity Drugs, By Region, 2019–2035 (Usd Billion)
- Table 19 Global Anti-obesity Drugs Market, For Peripherally Acting Anti-obesity Drugs, By Region, 2019–2035 (Usd Billion)
- Table 20 Global Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 21 Global Anti-obesity Drugs Market, For Oral, By Region, 2019–2035 (Usd Billion)
- Table 22 Global Anti-obesity Drugs Market, For Subcutaneous, By Region, 2019–2035 (Usd Billion)
- Table 23 Global Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 24 Global Anti-obesity Drugs Market, For Hospital Pharmacies, By Region, 2019–2035 (Usd Billion)
- Table 25 Global Anti-obesity Drugs Market, For Retail Pharmacies, By Region, 2019–2035 (Usd Billion)
- Table 26 Global Anti-obesity Drugs Market, For Online Pharmacies, By Region, 2019–2035 (Usd Billion)
- Table 27 Global Anti-obesity Drugs Market, By Region, 2019–2035 (Usd Billion)
- Table 28 North America Anti-obesity Drugs Market, By Country, 2019–2035 (Usd Billion)
- Table 29 North America: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 30 North America: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 31 North America: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 32 North America: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 33 North America: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 34 North America: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 35 Us: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 36 Us: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 37 Us: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 38 Us: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 39 Us: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 40 Us: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 41 Canada: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 42 Canada: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 43 Canada: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 44 Canada: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 45 Canada: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 46 Canada: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 47 Europe Anti-obesity Drugs Market, By Country, 2019–2035 (Usd Billion)
- Table 48 Europe: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 49 Europe: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 50 Europe: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 51 Europe: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 52 Europe: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 53 Europe: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 54 Germany: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 55 Germany: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 56 Germany: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 57 Germany: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 58 Germany: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 59 Germany: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 60 France: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 61 France: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 62 France: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 63 France: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 64 France: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 65 France: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 66 Uk: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 67 Uk: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 68 Uk: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 69 Uk: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 70 Uk: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 71 Uk: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 72 Spain: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 73 Spain: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 74 Spain: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 75 Spain: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 76 Spain: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 77 Spain: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 78 Italy: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 79 Italy: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 80 Italy: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 81 Italy: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 82 Italy: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 83 Italy: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 84 Russia: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 85 Russia: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 86 Russia: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 87 Russia: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 88 Russia: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 89 Russia: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 90 Rest Of Europe: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 91 Rest Of Europe: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 92 Rest Of Europe: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 93 Rest Of Europe: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 94 Rest Of Europe: Anti-obesity Drugs Market, By Route Of Administration, 2019–2035 (Usd Billion)
- Table 95 Rest Of Europe: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 96 Asia Pacific Anti-obesity Drugs Market, By Region, 2019–2035 (Usd Billion)
- Table 97 Asia Pacific: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 98 Asia Pacific: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 99 Asia Pacific: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 100 Asia Pacific: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 101 Asia Pacific: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 102 Asia Pacific: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 103 China: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 104 China: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 105 China: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 106 China: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 107 China: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 108 China: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 109 India: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 110 India: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 111 India: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 112 India: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 113 India: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 114 India: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 115 Japan: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 116 Japan: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 117 Japan: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 118 Japan: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 119 Japan: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 120 Japan: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 121 South Korea: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 122 South Korea: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 123 South Korea: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 124 South Korea: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 125 South Korea: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 126 South Korea: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 127 Malaysia: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 128 Malaysia: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 129 Malaysia: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 130 Malaysia: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 131 Malaysia: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 132 Malaysia: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 133 Thailand: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 134 Thailand: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 135 Thailand: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 136 Thailand: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 137 Thailand: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 138 Thailand: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 139 Indonesia: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 140 Indonesia: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 141 Indonesia: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 142 Indonesia: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 143 Indonesia: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 144 Indonesia: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 145 Rest Of Asia Pacific: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 146 Rest Of Asia Pacific: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 147 Rest Of Asia Pacific: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 148 Rest Of Asia Pacific: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 149 Rest Of Asia Pacific: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 150 Rest Of Asia Pacific: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 151 South America Anti-obesity Drugs Market, By Region, 2019–2035 (Usd Billion)
- Table 152 South America: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 153 South America: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 154 South America: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 155 South America: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 156 South America: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 157 South America: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 158 Brazil: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 159 Brazil: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 160 Brazil: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 161 Brazil: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 162 Brazil: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 163 Brazil: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 164 Mexico: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 165 Mexico: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 166 Mexico: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 167 Mexico: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 168 Mexico: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 169 Mexico: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 170 Argentina: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 171 Argentina: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 172 Argentina: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 173 Argentina: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 174 Argentina: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 175 Argentina: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 176 Rest Of South America: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 177 Rest Of South America: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 178 Rest Of South America: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 179 Rest Of South America: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 180 Rest Of South America: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 181 Rest Of South America: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 182 Middle East And Africa: Anti-obesity Drugs Market, By Country, 2019–2035 (Usd Billion)
- Table 183 Middle East And Africa: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 184 Middle East And Africa: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 185 Middle East And Africa: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 186 Middle East And Africa: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 187 Middle East And Africa: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 188 Middle East And Africa: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 189 Gcc Countries: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 190 Gcc Countries: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 191 Gcc Countries: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 192 Gcc Countries: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 193 Gcc Countries: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 194 Gcc Countries: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 195 South Africa: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 196 South Africa: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 197 South Africa: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 198 South Africa: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 199 South Africa: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 200 South Africa: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 201 Rest Of Mea: Anti-obesity Drugs Market, By Treatment Type, 2019–2035 (Usd Billion)
- Table 202 Rest Of Mea: Anti-obesity Drugs Market, For Appetite Suppressants, By Type, 2019–2035 (Usd Billion)
- Table 203 Rest Of Mea: Anti-obesity Drugs Market, By Drug Type, 2019–2035 (Usd Billion)
- Table 204 Rest Of Mea: Anti-obesity Drugs Market, By Mechanism Of Action, 2019–2035 (Usd Billion)
- Table 205 Rest Of Mea: Anti-obesity Drugs Market, Route Of Administration, 2019–2035 (Usd Billion)
- Table 206 Rest Of Mea: Anti-obesity Drugs Market, By Distribution Channel, 2019–2035 (Usd Billion)
- Table 207 Product Approval
- Table 208 Marketing Approval
- Table 209 Product Expansion
- Table 210 Facility Launch
- Table 211 Aquisition
- Table 212 Agreement
- Table 213 Eli Lilly And Company: Products Offered
- Table 214 Eli Lilly And Company: Key Developments
- Table 215 Astrazeneca: Product Offered
- Table 216 Astrazeneca: Key Developments
- Table 217 Gsk Plc: Products Offered
- Table 218 Gelesis: Product Offered
- Table 219 Cheplapharm Arzneimittel Gmbh: Products Offered
- Table 220 Novo Nordisk A/S: Products Offered
- Table 221 Novo Nordisk A/S: Key Developments
- Table 222 Rhythm Pharmaceuticals, Inc.: Products Offered
- Table 223 Rhythm Pharmaceuticals, Inc.: Key Developments
- Table 224 Kvk Tech, Inc.: Products Offered
- Table 225 Currax Pharmaceuticals Llc: Products Offered
- Table 226 Currax Pharmaceuticals Llc: Key Developments
- Table 227 Vivus Llc: Products Offered
- Table 228 Vivus Llc: Key Developments
- List Of Figures
- Figure 1 Global Anti-obesity Drugs Market: Structure
- Figure 2 Global Anti-obesity Drugs Market: Market Growth Factor Analysis (2024-2035) Source: Mrr Analysis
- Figure 3 Driver Impact Analysis (2024-2035)
- Figure 4 Restraint Impact Analysis (2024-2035)
- Figure 5 Porter's Five Forces Analysis: Global Anti-obesity Drugs Market
- Figure 6 Global Anti-obesity Drugs Market, By Treatment Type, 2024 & 2035 (Usd Billion)
- Figure 7 Global Anti-obesity Drugs Market Share (%), By Treatment Type, 2024
- Figure 8 Global Anti-obesity Drugs Market, By Drug Type, 2024 & 2035 (Usd Billion)
- Figure 9 Global Anti-obesity Drugs Market Share (%), By Drug Type, 2024
- Figure 10 Global Anti-obesity Drugs Market, By Mechanism Of Action, 2024 & 2035 (Usd Billion)
- Figure 11 Global Anti-obesity Drugs Market Share (%), By Mechanism Of Action, 2024
- Figure 12 Global Anti-obesity Drugs Market, By Route Of Administration, 2023 & 2035 (Usd Billion)
- Figure 13 Global Anti-obesity Drugs Market Share (%), By Route Of Administration, 2024
- Figure 14 Global Anti-obesity Drugs Market, By Distribution Channel, 2023 & 2035 (Usd Billion)
- Figure 15 Global Anti-obesity Drugs Market Share (%), By Distribution Channel, 2024
- Figure 16 Global Anti-obesity Drugs Market Share, By Region, 2024 & 2035 (Usd Billion)
- Figure 17 Global Anti-obesity Drugs Market Share, By Region, 2024 (%)
- Figure 18 North America Anti-obesity Drugs Market Share, By Country, 2024 & 2035 (Usd Billion)
- Figure 19 North America Anti-obesity Drugs Market Share, By Country, 2024 (%)
- Figure 20 Europe Anti-obesity Drugs Market Share, By Country, 2024 & 2035 (Usd Billion)
- Figure 21 Europe Anti-obesity Drugs Market Share, By Country, 2024 (%)
- Figure 22 Asia Pacific: Anti-obesity Drugs Market Share, By Country, 2024 & 2035 (Usd Billion)
- Figure 23 Asia Pacific: Multiple Sclerosis Treatment Devices Treatment Market Share, By Country, 2024 (%)
- Figure 24 South America: Anti-obesity Drugs Market Share, By Country, 2024 & 2035 (Usd Billion)
- Figure 25 South America: Anti-obesity Drugs Market Share, By Country, 2024 (%)
- Figure 26 Middle East And Africa: Anti-obesity Drugs Market Share, By Country, 2024 & 2035 (Usd Billion)
- Figure 27 Middle East And Africa: Anti-obesity Drugs Market Share, By Country, 2024 (%)
- Figure 28 Global Anti-obesity Drugs Market Players: Competitive Analysis, 2024
- Figure 29 Competitor Dashboard: Global Anti-obesity Drugs Market
- Figure 30 Eli Lilly And Company: Financial Overview Snapshot
- Figure 31 Eli Lilly And Company: Swot Analysis
- Figure 32 Astrazeneca: Financial Overview Snapshot
- Figure 33 Astrazeneca: Swot Analysis
- Figure 34 Gsk Plc: Financial Overview Snapshot
- Figure 35 Gsk Plc: Swot Analysis
- Figure 36 Novo Nordisk A/S: Financial Overview Snapshot
- Figure 37 Novo Nordisk A/S: Swot Analysis
- Figure 38 Rhythm Pharmaceuticals, Inc.: Financial Overview Snapshot
- Figure 39 Rhythm Pharmaceuticals, Inc.: Swot Analysis
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
